253 related articles for article (PubMed ID: 21163265)
1. Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
Cheng H; Woodgett J; Maamari M; Force T
J Mol Cell Cardiol; 2011 Oct; 51(4):607-13. PubMed ID: 21163265
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo.
Woulfe KC; Gao E; Lal H; Harris D; Fan Q; Vagnozzi R; DeCaul M; Shang X; Patel S; Woodgett JR; Force T; Zhou J
Circ Res; 2010 May; 106(10):1635-45. PubMed ID: 20360256
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases.
Zhai P; Gao S; Holle E; Yu X; Yatani A; Wagner T; Sadoshima J
J Biol Chem; 2007 Nov; 282(45):33181-91. PubMed ID: 17855351
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload.
Matsuda T; Zhai P; Maejima Y; Hong C; Gao S; Tian B; Goto K; Takagi H; Tamamori-Adachi M; Kitajima S; Sadoshima J
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20900-5. PubMed ID: 19106302
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts.
Huisamen B; Hafver TL; Lumkwana D; Lochner A
Cardiovasc Drugs Ther; 2016 Jun; 30(3):237-46. PubMed ID: 27180786
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration.
Singh AP; Umbarkar P; Guo Y; Force T; Gupte M; Lal H
Cardiovasc Res; 2019 Jan; 115(1):20-30. PubMed ID: 30321309
[TBL] [Abstract][Full Text] [Related]
7. The GSK-3 family as therapeutic target for myocardial diseases.
Lal H; Ahmad F; Woodgett J; Force T
Circ Res; 2015 Jan; 116(1):138-49. PubMed ID: 25552693
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy.
Hardt SE; Tomita H; Katus HA; Sadoshima J
Circ Res; 2004 Apr; 94(7):926-35. PubMed ID: 15001529
[TBL] [Abstract][Full Text] [Related]
9. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Webb IG; Nishino Y; Clark JE; Murdoch C; Walker SJ; Makowski MR; Botnar RM; Redwood SR; Shah AM; Marber MS
Cardiovasc Res; 2010 Aug; 87(3):494-503. PubMed ID: 20299330
[TBL] [Abstract][Full Text] [Related]
10. GSK-3 at the heart of cardiometabolic diseases: Isoform-specific targeting is critical to therapeutic benefit.
Umbarkar P; Ruiz Ramirez SY; Toro Cora A; Tousif S; Lal H
Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166724. PubMed ID: 37094727
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase-3beta is involved in the process of myocardial hypertrophy stimulated by insulin-like growth factor-1.
Seimi SK; Seinosuke K; Tsuyoshi S; Tomomi U; Tetsuaki H; Miki K; Ryuji T; Kenji I; Mitsuhiro Y
Circ J; 2004 Mar; 68(3):247-53. PubMed ID: 14993781
[TBL] [Abstract][Full Text] [Related]
12. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice.
Zhou J; Lal H; Chen X; Shang X; Song J; Li Y; Kerkela R; Doble BW; MacAulay K; DeCaul M; Koch WJ; Farber J; Woodgett J; Gao E; Force T
J Clin Invest; 2010 Jul; 120(7):2280-91. PubMed ID: 20516643
[TBL] [Abstract][Full Text] [Related]
13. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
14. Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure.
Tariq U; Uppulapu SK; Banerjee SK
Curr Drug Targets; 2021; 22(13):1568-1576. PubMed ID: 33655828
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.
Nagini S; Sophia J; Mishra R
Semin Cancer Biol; 2019 Jun; 56():25-36. PubMed ID: 29309927
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.
Fujita A; Takahashi-Yanaga F; Morimoto S; Yoshihara T; Arioka M; Igawa K; Tomooka K; Hoka S; Sasaguri T
Hypertens Res; 2017 Feb; 40(2):130-139. PubMed ID: 27628899
[TBL] [Abstract][Full Text] [Related]
18. The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model.
Baruah J; Hitzman R; Zhang J; Chaudhuri S; Mastej V; Wary KK
J Biol Chem; 2017 Dec; 292(50):20785-20798. PubMed ID: 29070680
[TBL] [Abstract][Full Text] [Related]
19. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
Amar S; Belmaker RH; Agam G
Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
[TBL] [Abstract][Full Text] [Related]
20. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
